Exicure Inc - Understand $xcur stock

$XCUR Market Cap: $5.502 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$500.0K

TTM

Gross Margin

Net Earnings

-$4.007M

TTM

Current Assets

$2.600M

Q3 2024

Current Liabilities

$3.655M

Q3 2024

Current Ratio

71.14%

Q3 2024

Total Assets

$10.63M

Q3 2024

Total Liabilities

$9.086M

Q3 2024

Book Value

$1.545M

Q3 2024

Cash

$343.0K

Q3 2024

P/E

-1.373

Nov 14, 2024 EST

Free Cash Flow

-$816.0K

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$0.00	$28.83M	-$483.0K	$16.61M	$1.296M	$118.0K	$9.719M	$1.036M	$2.390M
YoY Change	-100.0%	-6068.12%	-102.91%	1181.87%	998.31%	-98.79%	838.13%	-56.65%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$0.00	$28.83M	-$483.0K	$16.61M	$1.296M	$118.0K	$9.719M	$1.036M	$2.390M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	$12.65M	$10.89M	$13.09M	$9.960M	$8.570M	$7.820M	$7.050M	$3.540M	$5.410M
YoY Change	16.19%	-16.79%	31.4%	16.22%	9.59%	10.92%	99.15%	-34.57%
% of Gross Profit
Research & Development	$1.423M	$19.77M	$48.98M	$32.09M	$19.34M	$14.12M	$13.08M	$13.66M	$10.12M
YoY Change	-92.8%	-59.64%	52.61%	65.95%	36.98%	7.94%	-4.24%	34.97%
% of Gross Profit
Depreciation & Amortization	$634.0K	$1.163M	$1.123M	$770.0K	$390.0K	$360.0K	$230.0K	$180.0K	$130.0K
YoY Change	-45.49%	3.56%	45.84%	97.44%	8.33%	56.52%	27.78%	38.46%
% of Gross Profit
Operating Expenses	$15.00M	$30.66M	$62.07M	$42.05M	$27.91M	$21.94M	$20.13M	$17.20M	$15.53M
YoY Change	-51.08%	-50.61%	47.6%	50.64%	27.24%	9.0%	17.03%	10.74%
Operating Profit	-$15.00M	-$1.831M	-$62.55M	-$25.44M	-$26.62M	-$21.82M	-$10.41M	-$16.16M
YoY Change	719.01%	-97.07%	145.91%	-4.44%	21.99%	109.66%	-35.61%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Interest Expense	$0.00	$595.0K	$1.691M	$573.0K	$786.0K	$672.0K	$795.0K	$724.0K	$0.00
YoY Change	-100.0%	-64.81%	195.11%	-27.1%	16.96%	-15.47%	9.81%
% of Operating Profit
Other Income/Expense, Net	-$1.918M	-$542.0K	-$1.553M	$768.0K	$314.0K	-$594.0K	-$604.0K	-$779.0K	-$10.00K
YoY Change	253.87%	-65.1%	-302.21%	144.59%	-152.86%	-1.66%	-22.46%	7690.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Pretax Income	-$16.91M	-$2.373M	-$64.10M	-$24.67M	-$26.30M	-$22.41M	-$12.04M	-$16.94M	-$13.15M
YoY Change	612.77%	-96.3%	159.86%	-6.22%	17.37%	86.15%	-28.94%	28.83%
Income Tax	$0.00	$209.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.91M	-$2.582M	-$64.10M	-$24.67M	-$26.30M	-$22.41M	-$11.01M	-$16.94M	-$13.15M
YoY Change	555.07%	-95.97%	159.86%	-6.22%	17.36%	103.55%	-35.0%	28.83%
Net Earnings / Revenue		-8.96%		-148.49%	-2029.55%	-18994.07%	-113.29%	-1635.23%	-550.21%
Basic Earnings Per Share	-$2.11	-$0.56	-$0.72	-$0.28
Diluted Earnings Per Share	-$2.11	-$0.56	-$0.72	-$0.28	-$456.0K	-$544.1K	-$306.4K	-$431.0K	-$334.6K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Short-Term Investments	$816.0K	$8.577M	$39.14M	$82.10M	$110.8M	$26.30M	$25.80M	$19.60M	$18.70M
YoY Change	-90.49%	-78.09%	-52.33%	-25.9%	321.29%	1.94%	31.63%	4.81%
Cash & Equivalents	$816.0K	$8.577M	$34.64M	$33.30M	$48.50M	$26.30M	$25.80M	$19.60M	$18.70M
Short-Term Investments		$0.00	$4.497M	$48.80M	$62.30M
Other Short-Term Assets	$1.193M	$1.474M	$4.525M	$4.200M	$1.700M	$1.400M	$1.800M	$400.0K	$200.0K
YoY Change	-19.06%	-67.43%	7.74%	147.06%	21.43%	-22.22%	350.0%	100.0%
Inventory
Prepaid Expenses
Receivables			$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$200.0K
Other Receivables			$0.00	$0.00	$300.0K	$0.00	$0.00	$0.00	$100.0K
Total Short-Term Assets	$2.024M	$10.05M	$43.67M	$86.30M	$112.8M	$27.70M	$27.60M	$20.00M	$19.20M
YoY Change	-79.86%	-76.98%	-49.4%	-23.49%	307.22%	0.36%	38.0%	4.17%
Property, Plant & Equipment	$6.571M	$9.787M	$11.88M	$12.70M	$2.500M	$1.100M	$1.300M	$500.0K	$400.0K
YoY Change	-32.86%	-17.6%	-6.48%	408.0%	127.27%	-15.38%	160.0%	25.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.985M	$3.490M	$9.325M	$1.400M	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-14.47%	-62.57%	566.07%
Total Long-Term Assets	$9.556M	$13.28M	$21.20M	$14.10M	$2.500M	$1.100M	$1.400M	$600.0K	$400.0K
YoY Change	-28.03%	-37.38%	50.37%	464.0%	127.27%	-21.43%	133.33%	50.0%
Total Assets	$11.58M	$23.33M	$64.87M	$100.4M	$115.3M	$28.80M	$29.00M	$20.60M	$19.60M
YoY Change
Accounts Payable	$1.631M	$361.0K	$3.413M	$1.900M	$1.800M	$500.0K	$1.000M	$500.0K	$600.0K
YoY Change	351.8%	-89.42%	79.63%	5.56%	260.0%	-50.0%	100.0%	-16.67%
Accrued Expenses	$879.0K	$1.278M	$6.464M	$3.500M	$2.400M	$1.500M	$1.300M	$2.200M	$700.0K
YoY Change	-31.22%	-80.23%	84.69%	45.83%	60.0%	15.38%	-40.91%	214.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$6.873M	$0.00	$5.000M		$0.00	$1.200M	$0.00
YoY Change		-100.0%		-100.0%			-100.0%
Total Short-Term Liabilities	$2.510M	$1.639M	$34.07M	$13.70M	$31.10M	$2.000M	$3.400M	$12.20M	$1.300M
YoY Change	53.14%	-95.19%	148.66%	-55.95%	1455.0%	-41.18%	-72.13%	838.46%
Long-Term Debt	$0.00	$0.00	$0.00	$16.60M	$0.00	$4.900M	$4.900M	$4.700M	$0.00
YoY Change			-100.0%		-100.0%	0.0%	4.26%
Other Long-Term Liabilities	$6.039M	$6.767M	$19.57M	$8.600M	$3.400M	$800.0K	$800.0K	$1.300M	$0.00
YoY Change	-10.76%	-65.42%	127.55%	152.94%	325.0%	0.0%	-38.46%
Total Long-Term Liabilities	$6.039M	$6.767M	$19.57M	$25.20M	$3.400M	$5.700M	$5.700M	$6.000M	$0.00
YoY Change	-10.76%	-65.42%	-22.35%	641.18%	-40.35%	0.0%	-5.0%
Total Liabilities	$8.549M	$8.406M	$53.64M	$38.90M	$34.50M	$7.800M	$9.000M	$18.10M	$1.400M
YoY Change	1.7%	-84.33%	37.88%	12.75%	342.31%	-13.33%	-50.28%	1192.86%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	8.014M shares	4.619M shares	88.62M shares	87.20M shares
Diluted Shares Outstanding	8.014M shares	4.619M shares	88.62M shares	87.20M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $5.5022 Million

About Exicure Inc

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 6 full-time employees. The company went IPO on 2018-05-09. The firm is into exploring strategic alternatives to maximize stockholder value. The company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly traded organization. The firm is exploring transactions in industries unrelated to its historical operations. The company does not generate any revenues. The company wholly owned subsidiary is Exicure Operating Company that holds all material assets and conducts all business activities and operations of the Company.

Industry: Pharmaceutical Preparations Peers: Bellerophon Therapeutics, Inc. Benitec Biopharma Inc /entities/hura Cibus Inc Sonnet Biotherapeutics Holdings Inc CohBar Inc Ensysce Biosciences Inc Phio Pharmaceuticals Corp Unicycive Therapeutics Inc